Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Q1/11: Positive FDA Meeting, PLX to Resubmit Tali in Mid-2011
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Protalix BioTherapeutics (NYSE: PLX), PT $8.
Canaccord analyst says, "Positive recent meeting with FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Positive recent meeting with FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
